You generally are not required to provide information about yourself when you visit the Services. However, we may ask you for some or all of the following types of information when you request additional information about HETLIOZ® (tasimelteon). When you do so, our registration process requires you to provide your name, telephone number, email address and certain additional information about your interest in HETLIOZ® (collectively, "Subscription Data").
We also may collect certain information automatically when you visit the Services, including:
Vanda may use information that we collect through the Services to provide you with products, promotions, services, newsletters, and information in accordance with your preferences, and to respond to correspondence that we receive from you. Sometimes, we may use the information that we collect to contact you via email, telephone, or otherwise about HETLIOZ® (tasimelteon), Vanda, and our products and services; to learn more about your experience with HETLIOZ®; or to otherwise provide you with information that might be of interest to you. At your election at any time, you may choose to stop receiving future communications from Vanda ("opt-out;" see below for more information on how to opt-out).
We also may use information that we collect to maintain or administer the Services, perform business analyses, or for other internal purposes to improve the quality of our business, the Services, and other products and services we offer. For example, Vanda uses information collected automatically to help diagnose problems with its server, analyze trends, and administer the Services. We also may use information that you provide to customize and personalize your use of the Services and as otherwise described to you at the point of collection or pursuant to your consent.
We are committed to maintaining your trust, and we want you to understand when and with whom we may share the information we collect.
We take a number of steps to help protect against loss, misuse, unauthorized access, disclosure, alteration or destruction of the information you provide to us. Unfortunately, no data transmission over the Internet can be guaranteed to be 100% secure. As a result, Vanda cannot ensure the security of any information you provide, and you do so at your own risk.
The Services do not knowingly collect, use, or disclose personal information from children under the age of 13 without prior parental consent, except as permitted by the Children’s Online Privacy Protection Act (“COPPA”).
We may allow third parties to place and read their own cookies, pixel tags, web beacons, Local Shared Objects, and similar technologies to collect information through the Services. For example, our third-party service providers may use these technologies to collect information that helps us with traffic measurement, research, analytics, and providing you with relevant advertisements.
You may elect to avoid future communications from Vanda by sending an email to firstname.lastname@example.org with your electronic mail address.
Some web browsers may transmit “do-not-track” signals to the websites with which the user communicates. Because of differences in how web browsers incorporate and activate this feature, it is not always clear whether users intend for these signals to be transmitted, or whether they even are aware of them. Because there currently is no industry standard concerning what, if anything, websites should do when they receive such signals, we currently do not take action in response to these signals. If and when a final standard is established and accepted, we will reassess how to respond to these signals. In some cases, third parties may be able to collect information about a user’s online activities over time and across different websites when he or she uses our Services.
Vanda does not share information that it collects with third parties for the third party’s direct marketing purposes.
Vanda Pharmaceuticals Inc.
Attn: Privacy Statement
2200 Pennsylvania Ave NW
Washington DC 20037
The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® (tasimelteon) than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.
HETLIOZ® (tasimelteon) capsules are indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in adults and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older. HETLIOZ LQTM oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in patients 3 to 15 years of age.
Please see full US Prescribing Information.